MONTREAL and CHARLOTTE, N.C., Nov. 29, 2022 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of the Company's management team will host a virtual commercial deep-dive event on Tuesday, December 6, 2022 at 1:00 p.m. ET. The event will focus on the commercial opportunity for etripamil, the Company's lead investigational product, for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT).
Read more at newswire.cahello world
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
